Report overview
Oncolytic virus is a special virus that can beneficially infect and kill cancer cells. These are deployed as part of cancer immunotherapy and work by selectively targeting cancer cells and performing oncolytics. Oncolytic viruses can not only kill cancer cells directly, but also stimulate patients' own anti-tumor immune response.
This report contains market size and forecasts of Oncolytic Virus Cancer Immunotherapy in Global, including the following market information:
Global Oncolytic Virus Cancer Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Oncolytic Virus Cancer Immunotherapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Oncolytic Virus Cancer Immunotherapy include AstraZeneca, Amgen, F Hoffman-La Roche, Bristol-Myers Squibb, Novartis AG, Merck & Co., Inc., Pfizer, Biovex and Cell Genesys, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Oncolytic Virus Cancer Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Oncolytic Virus Cancer Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Oncolytic Virus Cancer Immunotherapy Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibodies
Checkpoint Inhibitors
Oncoloytic Viral Therapies and Cancer Vaccines
Global Oncolytic Virus Cancer Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Oncolytic Virus Cancer Immunotherapy Market Segment Percentages, by Application, 2021 (%)
Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and neck Cancer
Ovarian Cancer
Pancreatic Cancer
Others
Global Oncolytic Virus Cancer Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Oncolytic Virus Cancer Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Oncolytic Virus Cancer Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Oncolytic Virus Cancer Immunotherapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Amgen
F Hoffman-La Roche
Bristol-Myers Squibb
Novartis AG
Merck & Co., Inc.
Pfizer
Biovex
Cell Genesys
Crusade Laboratories
Genelux Corporation
Lokon Pharma
MultiVir
